Outcome of relapsed or refractory acute B-lymphoblastic leukemia patients and BCR-ABL-positive blast cell crisis of B-lymphoid lineage with extramedullary disease receiving inotuzumab ozogamicin

Acute lymphoblastic leukemia (ALL) can relapse in the extramedullary compartment, with or without medullary involvement. Response to treatment may be individual. We evaluated response to inotuzumab ozogamicin in 31 patients with relapsed/refractory B-ALL with extramedullary disease. Median age was 3...

Descripción completa

Detalles Bibliográficos
Autores principales: Kayser, Sabine, Sartor, Chiara, Luskin, Marlise R., Webster, Jonathan, Giglio, Fabio, Panitz, Nydia, Brunner, Andrew M., Fante, Matthias, Lutz, Christoph, Wolff, Daniel, Ho, Anthony D., Levis, Mark J., Schlenk, Richard F., Papayannidis, Cristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2022
Materias:
Article - Acute Lymphoblastic Leukemia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9425305/
https://www.ncbi.nlm.nih.gov/pubmed/35142153
http://dx.doi.org/10.3324/haematol.2021.280433

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9425305/
https://www.ncbi.nlm.nih.gov/pubmed/35142153
http://dx.doi.org/10.3324/haematol.2021.280433

Ejemplares similares